

LifeBond Raises \$20m in a Third Financing Round

May 23rd, 2011

LifeBond, a biosurgery device company has completed a \$20m fund raising, which was led by Giza Venture Capital and Aurum Ventures. Also participating in the round were existing investors: Pitango Venture Capital and Mr. Robert Taub, GlenRock Israel and The Zitelman Group. LifeBond CEO, Ishay Attar said "LifeBond is marching forward rapidly to provide solutions for major un-met needs in surgery. We welcome the new investors to the company"

The start-up company LifeBond, which is developing a line of products in bio-surgery, has raised \$20million in a third financing round. This financing round was led by Giza Venture Capital and Morris Kahn's Aurum Ventures. Also participating in the round were existing investors: Pitango and Mr. Robert Taub, founder and former CEO of Omrix Biopharmaceuticals, GlenRock Israel, Leon Recanati's investment company, and The Zitelman Group. Dr. Yuval Avni and Dr. Dan J. Gelvan will join the Company's Board of Directors, following this investment round.

LifeBond is developing surgical sealants and hemostats intended for preventing leakage and bleeding. Proceeds from the round will be used for completion of the pre-clinical and clinical phases of the Company's initial product: LifeSealGI™, a sealant indicated for reinforcement of gastro-intestinal anastomoses. Post-surgical leakage from anastomoses is currently a significant risk factor that can result in life threatening complications and costly re-operations. In certain surgical procedures the risk of leakage is up to 20% of overall procedures.

LifeBond anticipates that LifeSealGI™ will reach the market toward the end of 2012, pending regulatory approval. In addition, the company will continue to develop its severe bleeding control product, LifePatch™, which is based on the same technology platform.

LifeBond CEO Ishay Attar said "Closing this significant financing round in the current financial environment is a testament to the potential of LifeBond's technology. Surgical teams are actively seeking innovative wound closure products with improved performance and ease-of-use to seal surgical staple-lines and stop severe bleeding. We are looking forward to using the proceeds provided by this round to bring our first products to market as early as possible. Once approved, our products will become essential parts of the surgical toolbox and significantly improve surgical care."

Yuval Avni, a Partner at Giza who will join the company's Board of Directors added:

"We are excited to partner with LifeBond's management team and investors. We have been following LifeBond since its inception and we have been very impressed with the founders' vision and business execution. We believe there is tremendous market potential for the first product, as well as the underlying technology. As a surgeon, aware of the need for surgical sealants, I had no doubts about LifeBond after trying the products

myself and witnessing the impressive performance.. We look forward to working with LifeBond's team."

Ittai Harel, Partner at Pitango, and co-Chairman of LifeBond Board of Directors added:

Lifebond has made great progress during the last two years on multiple fronts. LifeBond's founders, Ishay Attar and Orahm Preiss-Bloom, have established an excellent team and have led the company towards significant accomplishments in product development, manufacturing and clinical studies; accomplishments that have clearly demonstrated the potential of the company's lead product and technology. We are encouraged by the company's progress and strongly believe in its potential. We welcome Giza and Aurum to the company, and look forward to working together, as the company progresses to clinical and commercial phases.

About LifeBond:

LifeBond is developing a line of biosurgical products for prevention of surgical leakage and bleeding. The company was founded in 2007 by LifeBond CEO, Ishay Attar, who previously served as the VP of Misgav Venture Accelerator, LifeBond VP Operations, Orahm Preiss-Bloom, who conducted biomaterial research at Columbia University, and Nir Mashkif. The company received seed funding from the Trendlines Israel Fund, followed by a \$1.5M Round A financing rounded by GlenRock Israel. In 2009 the company secured additional \$8.5M from Pitango and Mr. Robert Taub. The Company's headquarters is located in Caesarea Industrial Park. More on LifeBond: www.life-bond.com

About Giza:

Giza Venture Capital established in 1992, is a pioneer investor in seed and early-stage technology companies. Giza currently manages five funds totaling about US\$600 million. Giza investment professionals bring wealth of expertise and experience in Communications, Semiconductors, Information Technology, Enterprise Software, Life Sciences, CleanTech, Media, Internet and Entertainment. Giza established an office in Singapore in 2001 and is actively involved in supporting its Israeli related portfolio companies to expand and partner in the Greater China region. Giza has invested in around 100 companies in the sectors of Communications, Information Technology, Enterprise Software, CleanTech and Life Sciences, with more than 30 successful exits. More on Giza: <http://www.gizavc.com/>

About Aurum:

Aurum Ventures MKI is the technology investment arm of Morris Kahn, a prominent business man, philanthropist and entrepreneur. Aurum Ventures MKI invests in Israeli

and Israel related companies in the fields of life sciences and clean-tech in all stages of development. For further information please visit: www.aurum.co.il

About Pitango:

Pitango Venture Capital, the leading venture capital firm in Israel, has been investing in technology entrepreneurs since 1993. With offices in Israel and Silicon Valley, California, Pitango currently manages several venture funds totaling over \$1.3 billion in committed capital invested in more than 100 companies. Pitango invests in high-growth companies in various stages, from seed and early stages to growth and late-stage, and supports them as they grow. Pitango's investment focus includes: Communications; Networking & Storage; Wireless, Cellular and Mobile technologies; Enterprise Software, Internet and Media; Healthcare & Life Sciences, and Clean Technologies. More on Pitango: www.pitango.com

About Mr. Robert Taub:

Mr. Taub is the Founder and former CEO of Omrix Biopharmaceuticals, a company specializing in the manufacturing of fibrin-based surgical hemostats. In December 2008 Omrix was acquired by Johnson&Johnson for \$438M and today it operates as a fully owned subsidiary.

More on Robert Taub: www.recoly.com/about

About GlenRock:

GlenRock is an investment company owned by Leon Recanati. It was founded in 2003 to invest in advanced technology and life-science companies. GlenRock's major investments are: Quigo (acquired by AOL), Kamada, Evogene, Mobileye and others. Leon Recanati is GlenRock's Chairman and General Manager, the leading partners and managers are Dr. Shula Recanati and Ziv Kop.

More on GlenRock: www.grg.co.il

About Zitelman Group:

The Zitelman Group is a Rockville, Maryland-based investment firm which invests in early stage technology and life science ventures, as well as residential and commercial real estate projects. Formed in 1985, TZG expanded its geographic focus to include

Israel, where it has invested in two early stage funds and has made direct investments in four companies.

More on The Zitelman Group: www.tzg.com